Date: 2011-09-07
Type of information: Licensing agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: Medigene (Germany) Pharmanova (Serbia)
Therapeutic area: Infectious diseases - Gynecology - Women's health
Type agreement: licensing commercialisation
Action mechanism:
Disease: genital warts
Details: MediGene has signed an exclusive license and supply agreement with Pharmanova d.o.o. for the supply and commercialization of Veregen® ointment in Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania, for the treatment of genital warts. Pharmanova will be responsible for the drug approval procedure in the above mentioned countries (except Slovenia). MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and Switzerland, with Laboratoires Expanscience for France, with Meditrina Pharmaceuticals for Greece, Cyprus, Romania and Bulgaria, and with a number of other partners across Europe, America, and Asia. MediGene is planning to continue this global licensing strategy.
Financial terms: MediGene is entitled to successive payments, due upon the achievement of set regulatory and sales milestones, and will receive double-digit royalties on sales of Veregen®. Further financial details of the agreement were not disclosed.
Latest news:
